Mahira
El Sayed
,
MSc, MD
Ain Shams University
Cairo
,
Egypt
Chair
IPC Board Member
CLOSING GAPS IN PSORIASIS CARE FOR DIVERSE SKIN TYPES
The Diverse Skin Tones Working Group is dedicated to addressing unmet needs in psoriasis care for diverse skin tones. The group focuses on enhancing dermatologists’ ability to diagnose and treat psoriasis in individuals with diverse skin accurately and collaborates with organizations, including patient and dermatology associations, to promote equitable care.
In 2025, the group achieved two significant milestones: publishing Psoriasis in People With Skin of Color: An Evidence-Based Update in the International Journal of Dermatology and launching Visual Differences in Psoriasis on Diverse Skin Tones, a clinical education tool aimed at improving diagnostic accuracy and advancing equitable care for patients with diverse skin tones.
Looking ahead, the Diverse Skin Tones Working Group will continue developing educational tools and resources for clinicians while fostering collaborations with organizations such as the GPA, IFPA, and the Skin of Color Society.
View more resources on diverse skin.
| Cookie | Duration | Description |
|---|---|---|
| cookielawinfo-checkbox-analytics | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics". |
| cookielawinfo-checkbox-functional | 11 months | The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional". |
| cookielawinfo-checkbox-necessary | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary". |
| cookielawinfo-checkbox-others | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other. |
| cookielawinfo-checkbox-performance | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance". |
| viewed_cookie_policy | 11 months | The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data. |
A new IPC paper in JAAD presents five priorities for improving metabolic screening, advancing GLP-1 research in the context of psoriasis, and defining the dermatologist’s role in managing cardiometabolic risk in psoriasis patients.
IPC Jr. Councilor Mio Nakamura speaks with Dr. John Koo about how personality traits, including borderline personality disorder, shape clinical interactions and shares practical strategies for dermatologists to build stronger patient relationships.
Recordings from the IPC Fellows Research Class #1: Global and Collaborative Research in Psoriasis are now available. Program Chairs Peter van de Kerkhof, MD, PhD, and María Julia Cura, MD, led a faculty of international experts through sessions on unresolved questions in the era of effective psoriasis therapies, building global research collaborations, and connecting psoriasis research across disciplines. Watch to hear from Wolf Henning Boehncke, MD, MA, Christopher Griffiths, OBE, MD, FMedSci, and Georg Stingl, MD, as they share perspectives shaping the next generation of psoriasis research.
The IPC Resource Library now includes a dedicated Research Skills category, bringing together videos, articles, and presentations focused on building stronger research capabilities in psoriasis. Browse the current collection to find resources on topics from collaborative research methods to career development for researchers at every stage.
Rare ADAR1 gene mutations drive a distinct, interferon-fueled psoriasis subtype, and it responds to JAK1 and TYK2 inhibitors rather than standard IL-17/IL-23 biologics.
IPC Councilor Anna Lopez Ferrer, MD, PhD, reviews PURE-4, a four-item tool that helps dermatologists screen psoriasis patients for psoriatic arthritis (PsA) risk. She traces its evolution across three studies (2018–2026) into a validated predictor of early PsA.
IPC Councilor André Lucas Ribeiro, MD, reframes PsA as a slow transition from psoriasis, not a sudden event, opening the door to disease interception. He outlines the steps needed to get there, from harmonizing definitions to reducing inflammatory burden.